Please ensure Javascript is enabled for purposes of website accessibility

Why Shares in Celldex Therapeutics Dropped 10% Today

By Todd Campbell - Jan 13, 2016 at 7:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A broad market sell-off took a big toll on biotech stocks.

Source: Celldex Therapeutics

What: Sellers indiscriminately punished stocks today, and Celldex Therapeutics (CLDX -5.84%) didn't escape today's stock market rout unscathed. Despite no new news to digest, the company's shares tumbled 12.1% in today's session.

So what: The clinical-stage drug developer is working on cancer treatments, and its most advanced drug in development is Rintega, a therapy for the treatment of a rare form of brain cancer known as glioblastoma.

Last year, independent monitors took an interim look at data from Rintega's ongoing phase 3 trial and recommended the trial continue as planned. Another interim review is expected early this year, and the trial is slated to wrap up completely in November.

Now what: Investors are derisking their portfolios to play defense, and that means they're exiting shares in companies where binary events, such as the planned completion of Rintega's trial, could expose them to hit-or-miss returns.

No one knows whether Rintega's trial will show that it helps glioblastoma patients live longer or if the drug will prove to be safe enough to pass muster with regulators, but investors can speculate that a FDA decision on Rintega won't happen until 2017 (unless the trial is halted early), and that means there's not a whole heck of a lot of incentive for short-term investors to stick around.

This shortsightedness, however, could present an opportunity for risk-tolerant investors who approach the markets with a longer time horizon. After all, the need for new glioblastoma therapies is big, and Celldex Therapeutics' shares have retreated 52% since last June and nearly 23% already this year. 

Todd Campbell owns shares of Celldex Therapeutics. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Celldex Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
$35.28 (-5.84%) $-2.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.